• Bradykinin: From Vascular Signal to Translation

  2026-08-08

  Bradykinin is more than a vasodilator peptide: it is a controllable physiological challenge for studying endothelial relaxation, vascular permeability, smooth muscle responses, pain, and inflammation. This thought-leadership article connects vascular assay design with the TRPM7/calcineurin/Drp1 mitochondrial mechanism reported in diabetic cognitive dysfunction while clearly separating established evidence from hypothesis-generating translational opportunities.

• PF-573228: FAK Inhibitor Workflow Guide

  2026-08-07

  Use PF-573228 to connect focal adhesion signaling with matrix mechanics, cancer-cell behavior, and angiogenesis phenotypes. This practical guide combines pathway validation, migration assays, odontoblast-like differentiation workflows, and troubleshooting for more interpretable FAK inhibition studies.

• D-Luciferin Sodium Salt: Advancing Firefly Luciferase Imagin

  2026-08-07

  D-Luciferin sodium salt is driving the evolution of ATP-dependent bioluminescence assays with unmatched sensitivity and reproducibility, especially for in vivo monitoring of cell metabolism and immunotherapy workflows. This article explores the latest experimental innovations, protocol optimizations, and troubleshooting strategies that set APExBIO’s D-Luciferin sodium salt apart for oncology and cell biology applications.

• Biomimetic Microparticles Disrupt Tumor pH for Chemo-Immunot

  2026-08-06

  This study introduces a biomimetic microparticle system co-delivering syrosingopine and a doxorubicin prodrug to simultaneously disrupt intracellular and extracellular pH homeostasis in tumor cells. The approach enhances both chemotherapeutic cytotoxicity and anti-tumor immune responses, offering a synergistic strategy to overcome immune suppression in the tumor microenvironment.

• Tetrandrine Alkaloid: Next-Gen Ion Channel Modulation in Res

  2026-08-06

  Explore how Tetrandrine, a bioactive alkaloid, is advancing ion channel modulation and neuroinflammation research. This article offers a novel, comparative perspective on Tetrandrine's mechanisms and research workflows, setting it apart from prior coverage.

• IMPDH Inhibition Suppresses PEDV Replication via Host Metabo

  2026-08-05

  This study reveals that porcine epidemic diarrhea virus (PEDV) hijacks host IMPDH-dependent guanine nucleotide biosynthesis to facilitate its replication. Both genetic and pharmacological inhibition of IMPDH, including with Merimepodib (VX-497), significantly reduces PEDV proliferation, highlighting a promising host-directed antiviral target for veterinary coronaviruses.

• Influenza Hemagglutinin (HA) Peptide: Evidence-Based Tag Uti

  2026-08-05

  Influenza Hemagglutinin (HA) Peptide is a rigorously validated epitope tag used in protein detection and purification. Its high solubility, stability, and specificity enable precise immunoprecipitation with anti-HA antibodies. This article details the biological rationale, mechanism, benchmarks, and workflow parameters for optimal HA tag peptide use.

• CUDC-907: Dual PI3K and HDAC Inhibitor for Cell Studies

  2026-08-04

  CUDC-907 is a dual PI3K and HDAC inhibitor suited for in vitro cancer research, enabling simultaneous modulation of critical cell signaling and epigenetic pathways. It is not intended for diagnostic, clinical, or therapeutic applications, and its use is strictly limited to controlled laboratory workflows. Researchers should use this compound for studies of cell cycle arrest and apoptosis, with attention to storage and solubility constraints.

• Z-IETD-FMK in Apoptosis Research: Beyond Caspase-8 Inhibitio

  2026-08-04

  Explore the advanced utility of Z-IETD-FMK, a potent caspase-8 inhibitor, in dissecting apoptosis and immune cell activation. This article delves into unique experimental strategies and recent insights, setting it apart as an essential guide for researchers in cell death and immune modulation.

• Targeting DHHC9-Mediated STRN4 Palmitoylation in Cancer Meta

  2026-08-03

  This study identifies DHHC9-mediated palmitoylation of STRN4 as a critical driver of YAP-dependent cancer metastasis. Pharmacological inhibition of DHHC9 suppresses tumor cell migration by disrupting the Hippo pathway, offering a novel therapeutic target for adenocarcinoma intervention.

• Structure-Based Discovery of Natural Inhibitors for SARS-CoV

  2026-08-03

  This article analyzes a structure-based virtual screening study that identified thymopentin and oleuropein as potent natural product inhibitors of the SARS-CoV-2 NSP15 endoribonuclease. The findings highlight the potential of computational drug discovery for targeting viral immune evasion and inform future antiviral strategies.

• Evaluating Commercial Protease Inhibitor Libraries for COVID

  2026-08-02

  This review critically assesses commercial protease inhibitor and protein–protein interaction inhibitor libraries as resources for virtual screening in COVID-19 drug design. The paper highlights gaps in the documentation of compound selection, design rationale, and validation, underscoring the need for higher transparency and more robust library curation in early-stage drug discovery.

• CX-5461: RNA Polymerase I Inhibitor Workflows in Cancer Rese

  2026-08-01

  CX-5461 is a potent RNA polymerase I inhibitor that enables targeted inhibition of ribosome biogenesis, supporting advanced cancer research workflows and combinatorial therapy strategies. This article delivers practical protocols, troubleshooting guidance, and key innovations for using APExBIO’s CX-5461 in both solid tumor models and studies of chemoresistance.

• Z-LEHD-FMK in Translational Apoptosis: Precision Tools for C

  2026-07-31

  Explore how Z-LEHD-FMK, a selective irreversible caspase-9 inhibitor, advances apoptosis research beyond standard assays—revealing new strategies for cell death detection, neuroprotection, and cardioprotection. This article uniquely bridges mechanism, protocol, and translational insight.

• MK-5108 (VX-689): Translational Aurora A Inhibition Beyond R

  2026-07-31

  Explore how MK-5108 (VX-689) redefines selective Aurora A kinase inhibition, with unique insight into its mechanism, assay protocol optimization, and practical implications for tumor cell proliferation studies. Discover an advanced, evidence-driven resource for cancer research.

15354 records 1/1024 page Next 12345 下5页 Last page